Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference
October 23 2018 - 7:00AM
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP)
("Cyclacel" or the "Company"), a biopharmaceutical company
developing innovative medicines based on cancer cell biology,
announces that the Company will present at the 4th Annual Dawson
James Small Cap Growth Conference on October
30 at 3:00 p.m. ET, in the Preserve Ballroom C (Track 1)
at the Wyndham Grand Hotel in Jupiter, Florida. Spiro
Rombotis, President & Chief Executive Officer, will provide an
overview of the Company and progress in key programs.
A live webcast of the presentation will be available through the
Company's corporate website: www.cyclacel.com. The webcast
will be archived for 90 days.
About Cyclacel Pharmaceuticals, Inc.Cyclacel
Pharmaceuticals is a clinical-stage biopharmaceutical company using
its expertise in cell cycle, transcriptional regulation and DNA
damage response biology in cancer cells to develop innovative
medicines. Cyclacel's transcriptional regulation program is
evaluating CYC065, a CDK inhibitor, in patients with advanced
cancers. The DNA damage response program is evaluating a sequential
regimen of sapacitabine and seliciclib, a CDK inhibitor, in
patients with BRCA positive, advanced solid cancers. CYC140, a
Polo-like-kinase 1 (PLK-1) inhibitor, is ready to start
investigation in cancer patients. Cyclacel's strategy is to build a
diversified biopharmaceutical business focused in hematology and
oncology based on a pipeline of novel drug candidates. For
additional information, please visit www.cyclacel.com.
Forward-looking StatementsThis news release
contains certain forward-looking statements that involve risks and
uncertainties that could cause actual results to be materially
different from historical results or from any future results
expressed or implied by such forward-looking statements. Such
forward-looking statements include statements regarding, among
other things, the efficacy, safety and intended utilization of
Cyclacel's product candidates, the conduct and results of future
clinical trials, plans regarding regulatory filings, future
research and clinical trials and plans regarding partnering
activities. Factors that may cause actual results to differ
materially include the risk that product candidates that appeared
promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later clinical trials,
trials may have difficulty enrolling, Cyclacel may not obtain
approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements,
and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of
product candidates. You are urged to consider statements that
include the words "may," "will," "would," "could," "should,"
"believes," "estimates," "projects," "potential," "expects,"
"plans," "anticipates," "intends," "continues," "forecast,"
"designed," "goal," or the negative of those words or other
comparable words to be uncertain and forward-looking. For a further
list and description of the risks and uncertainties the Company
faces, please refer to our most recent Annual Report on Form 10-K
and other periodic and other filings we file with the Securities
and Exchange Commission and are available at www.sec.gov. Such
forward-looking statements are current only as of the date they are
made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts Company: Paul McBarron, (908)
517-7330, pmcbarron@cyclacel.com Investor Relations:
Russo Partners LLC, Alexander Fudukidis, (646)
942-5632, alex.fudukidis@russopartnersllc.com
© Copyright 2018 Cyclacel Pharmaceuticals, Inc. All Rights
Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Sep 2023 to Sep 2024